MLchartDataset catalogue

Efocipegtrutide

Term · Oncology and biomedicine · MLC-T-ONC-013228

A long-acting glucagon/gastric inhibitory peptide (GIP)/glucagon-like peptide-1 (GLP-1) triple receptor agonist conjugated with constant region of human immunoglobulin via a non-peptidyl flexible linker, with potential antihyperglycemic, anti-inflammatory and anti-fibrotic activities. Upon administration, efocipegtrutide binds to and activates multiple incretin receptors, including glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), which may decrease liver fat accumulation, inflammation and fibrogenesis, and normalize blood glucose levels.

Table 1. Record
IdentifierMLC-T-ONC-013228
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013228",
  "term": "Efocipegtrutide",
  "field": "Oncology and biomedicine",
  "definition": "A long-acting glucagon/gastric inhibitory peptide (GIP)/glucagon-like peptide-1 (GLP-1) triple receptor agonist conjugated with constant region of human immunoglobulin via a non-peptidyl flexible linker, with potential antihyperglycemic, anti-inflammatory and anti-fibrotic activities. Upon administration, efocipegtrutide binds to and activates multiple incretin receptors, including glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), which may decrease liver fat accumulation, inflammation and fibrogenesis, and normalize blood glucose levels.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/efocipegtrutide/"
}

Record 6,409 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.